Keyphrases
Adrenal Insufficiency
15%
Body Composition
12%
Body Mass Index
16%
Brain Development
14%
Brain Function
15%
Brain Structure
9%
Brain Volume
9%
Cell Function
16%
Children with Type 1 Diabetes
36%
Clinical Presentation
11%
Clinical Trials
9%
Continuous Glucose Monitoring
15%
Control Subjects
10%
Cortisol Assay
9%
Counterregulatory Response
19%
Cystic Fibrosis
23%
Diabetes
20%
Diabetic Ketoacidosis
11%
Elexacaftor-tezacaftor-ivacaftor
9%
Epinephrine
12%
Glucagon
31%
Glucose Intolerance
9%
Glycemia
12%
Glycemic Control
29%
Gray Matter Volume
10%
Hemoglobin A1c (HbA1c)
30%
High-density Diffuse Optical Tomography
14%
Hyperglycemia
22%
Hypoglycemia
53%
Hypoglycemia-associated Autonomic Failure
12%
Insulin
24%
Insulin Secretion
13%
Insulin Sensitivity
10%
Insulin Therapy
11%
Longitudinal Assessment
12%
Memory Function
9%
Metformin
10%
Non-diabetic
15%
Obesity
10%
Plasma Glucose
23%
Positron Emission Tomography
13%
Resistance Training
9%
Treatment Options
17%
Type 1 Diabetes Mellitus (T1DM)
100%
Type 2 Diabetes Mellitus (T2DM)
34%
Type I Diabetes
79%
White Matter
12%
White Matter Volume
12%
Young children
32%
Youth Studies
10%
Medicine and Dentistry
Adolescence
10%
Adolescent
13%
Adrenal Insufficiency
15%
Body Mass Index
12%
Brain Development
6%
Brain Function
7%
Clinical Trial
9%
COVID-19
9%
Cystic Fibrosis
15%
Diabetes
17%
Diabetes in Adolescents
16%
Diabetes Mellitus
7%
Diabetic Ketoacidosis
5%
Disease
6%
Dual-Energy X-Ray Absorptiometry
5%
Glucose Metabolism
5%
Glycemic Control
19%
Glycon
9%
Hemoglobin A1c
14%
Hydrocortisone
9%
Hypoglycemia
22%
Immunoassay
5%
Insulin Dependent Diabetes Mellitus
24%
Insulin Resistance
5%
Insulin Sensitivity
7%
Insulin Treatment
5%
Maturity Onset Diabetes of the Young
28%
Optical Tomography
9%
Pediatrics
9%
Pediatrics Patient
5%
Positron Emission Tomography
10%
Randomized Clinical Trial
5%
Resistance Training
9%
Toddlers
12%
Type 1 Diabetes
8%